Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® ...

Practical, office-based administration: Cretostimogene does not require prophylactic medication (e.g., anticholinergics), operating room time, additional cystoscopy, or anesthesia-dosing and aligns ...

A new treatment combination - Keytruda plus Padcev - is now approved for use before and after bladder‑removal surgery, ...

Pfizer (NYSE:PFE) draws healthcare-sector attention as a new bladder-cancer approval and an acquisition-built obesity program ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after ...

Muscle-invasive bladder cancer remains a significant clinical challenge, due in part to the highly aggressive nature of the ...

CG Oncology (CGON) reported durable responses and bladder preservation in patients with high-risk Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer in its p ...

The FDA approved pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa (Keytruda Qlex) in combination with ...

Patients saw improved event-free survival and overall survival with presurgical Imfinzi and chemotherapy followed by surgery and postsurgical Imfinzi. Treatment with Imfinzi (durvalumab) before and ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...